The University of Manchester

Renovo Limited

Sally Freeman

Sarah Glenys Moore

Mark W J Ferguson

Mark William James Ferguson

Mark William Ferguson

Ian Stratford

Stuart McRae Allan

Mohammed Jaffor

David Brough

Alex George Baldwin

Sarah G Jones

Inhibitor compounds are disclosed. The compounds are effective in the treatment of diseases or conditions in which interleukin 1 &#x3b2; activity is implicated. Methods of synthesis of the compounds, as well as pharmaceutical compositions comprising the compounds are also disclosed.

Cyclic diarylboron derivatives as NLRP3 inflammasome inhibitors

The present invention concerns analogues of M6P for use in promoting the healing of wounds or fibrotic disorders with reduced scarring, together with methods for doing same.

Pharmaceutical composition

A bioreductive conjugate comprises a bioreductive moiety with at least one therapeutic agent linked thereto and physiologically acceptable derivatives thereof. The bioreductive moiety incorporates an aromatic ring substituted with a nitro group and the conjugate is such that bioreduction of the nitro group causes release of the therapeutic agent by a through bond elimination and the residue of the bioreductive moiety to undergo an intramolecular cyclization reaction in which the nitrogen of the original nitro group provides an atom of the thus formed ring.

Drug targeting

Growing community of inventors

Manchester, United Kingdom

Sally Freeman